Dry direct compression of 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-amino-6-chloropurine begins with control of residual moisture and particle size. A compendial lot with water content ≤ 0.5% w/w by USP <921> and D90 ≤ 75 µm is pre-screened through a 500 µm sieve before charging to a bin blender together with microcrystalline cellulose NF, anhydrous lactose NF, crospovidone NF, and colloidal silicon dioxide NF. The free-flowing blend is mixed at 25 rpm for 20 min in a 300 L bin blender, then magnesium stearate NF is added through a 600 µm sieve and lubricated for 3 min at 12 rpm. Final blend uniformity is assessed by stratified sampling using an HPLC method validated per ICH Q2(R1); acceptance requires mean assay 90.0–110.0% of label claim and RSD ≤ 5.0% in 10 stratified samples. Compression on a rotary tablet press equipped with a force feeder and B-tooling applies precompression 8–12 kN and main compression 15–25 kN; tablet hardness is maintained at 70–110 N, thickness at 3.0–4.5 mm, and friability ≤ 1.0% w/w per USP <1216>. The terminal immediate-release tablets are film-coated with a hypromellose-based Opadry II system in a perforated pan at inlet air 60–70°C, bed temperature 35–40°C, and spray rate 8–15 g/min/kg. Disintegration time is verified per USP <701> with a limit of ≤ 15 min in 0.1 N HCl at 37°C. Controlled room conditions of 45–50% RH and 20–25°C are specified for compression because the two acetoxy groups are hygroscopic and prolonged exposure above 60% RH can increase hydrolysis and punch sticking. The exact active loading is product-specific and must be justified by blend uniformity and dissolution data; published data for this specific configuration is limited.

What Happens to the 6-Chloro and Acetoxy Groups in High-Shear Granulation?

High-shear wet granulation of the compound in aqueous media is constrained by the two acetyl ester side-chain groups and the 6-chloro purine substituent. In an aqueous binder system above pH 6.0, deacetylation of the side chain becomes measurable during the wet massing phase; therefore hydroalcoholic systems based on ethanol or isopropyl alcohol with polyvinylpyrrolidone K30 at 3–5 wt% solids are preferred. Granulation in a 25 L high-shear mixer is run at impeller 250–350 rpm and chopper 1500–2000 rpm for 3–5 min after binder addition, with wet mass torque held at 5–9 N·m to avoid over-wetting. The granules are wet-milled through a 1.5 mm screen and dried in a fluid-bed dryer at inlet air 45–55°C, product temperature not exceeding 35°C, until LOD ≤ 1.5% w/w by infrared balance. The dried granules are dry-milled through a 1.0 mm screen on a conical mill at 2000 rpm. Blending with crospovidone NF, colloidal silicon dioxide NF, and magnesium stearate NF follows the same stratified uniform blend acceptance as direct compression. The final film-coated tablet uses a coating dispersion with inlet air 60–70°C, bed temperature 35–40°C, and pan speed 2–6 rpm. A specification of related substances by HPLC at ≤ 1.0% total and any individual unspecified impurity ≤ 0.5% is referenced to ICH Q3B. For this exact molecule, published data on aqueous granulation degradation kinetics is limited; process development batches must bracket moisture, pH, and temperature to identify the deacetylation threshold before scale-up.

Capsule Filling Material Attributes and Segregation Control

For hard-shell capsules, the API is blended with milled lactose monohydrate NF and pregelatinized starch NF to a final fill weight of 180–350 mg in size 0 or size 1 hydroxypropyl methylcellulose capsules. Because the compound is lipophilic and may carry electrostatic charge, blending is conducted at 20–25°C and 40–45% RH; the API is pre-dispersed with a portion of excipient through a 60-mesh screen. The blend is mixed in a diffusion mixer at 25 rpm for 20 min. Capsule filling on an automatic tamping-pin machine is performed at 40,000–70,000 capsules/h with fill weight monitored every 15 min; acceptance for individual weight variation follows USP <905> with a limit of ± 7.5% for fill weights below 250 mg or ± 5.0% for fill weights ≥ 250 mg, depending on the approved weight. The filled capsules are run through a metal detector with ferrous, non-ferrous, and stainless steel test probes set at 0.5 mm, 0.8 mm, and 1.0 mm, respectively. Disintegration per USP <701> is ≤ 15 min in water at 37°C. Terminal product is a single-piece HPMC capsule containing a white to off-white powder blend; HPMC capsules are selected to minimize aldehyde-induced crosslinking risk and to meet halal/kosher supply requirements when relevant.

Dry granulation is applied where the API is moisture- and heat-sensitive enough that both aqueous and hydroalcoholic granulation create unacceptable deacetylation or 6-chloro hydrolysis. In roller compaction, a preblend of the API, microcrystalline cellulose NF, lactose monohydrate NF, croscarmellose sodium NF, and colloidal silicon dioxide NF is compacted at hydraulic pressure 40–70 kN, roll speed 5–10 rpm, and gap 2.0–3.0 mm. Ribbon density is checked every 10 min with a helium pycnometer against a target 1.05–1.20 g/cm³; if ribbon density falls below 1.00 g/cm³, the compaction force is increased in 5 kN increments. Milling through a 0.8 mm screen yields granules with a D50 of 180–250 µm and a Hausner ratio ≤ 1.25, measured per USP <1174>. The granules are lubricated with magnesium stearate NF at 0.5–0.75 wt% for 3 min. Tablet compression targets tensile strength 1.0–1.8 MPa and ejection force below 500 N to avoid picking because the acetoxy-containing molecule can soften under shear-induced heat. The terminal film-coated tablet, or alternatively the granule-filled capsule, is packaged in high-density polyethylene bottles with desiccant to maintain below 45% RH headspace during shelf life. For this specific compound, dry granulation is the preferred path when the API exhibits punch sticking or compactibility below 0.5 g/cm³ in direct compression.

When Oral Granules in Unit-Dose Sachets Are Required for Dose Flexing

For patients requiring weight-based dose adjustment or unable to swallow monolithic solid forms, the API is converted into free-flowing granules filled into single-dose sachets. The granulation process is dry roller compaction or low-moisture solvent granulation using isopropyl alcohol, producing granules with particle size distribution 75–500 µm and LOD ≤ 1.0% w/w. Flowability is verified on a Schulze RST-XS shear tester with a flow function coefficient ffc > 7.0. The granules are filled into laminated aluminum/polyethylene sachets at 20–25°C and ≤ 40% RH; fill weight variation follows USP <905> with a limit of ± 7.5% for weights below 250 mg. Disintegration or dispersion in 50 mL water at 25°C occurs within 3 min under manual stirring; the resulting dispersion is administered immediately. The primary packaging moisture vapour transmission rate is ≤ 0.001 g/m²/day to protect the ester groups from hydrolysis. Terminal product is a single-dose granule sachet labelled for oral administration after dispersion; the sachet is not a sustained-release form and must be consumed within 30 min of reconstitution.

Injectable Vehicle Limits and the Aseptic Filtration Boundary for a Hydrolytically Labile API

Parenteral use of this compound requires dissolution in a co-solvent system because free aqueous solubility of the diacetate is low. Screening vehicles include polyethylene glycol 400 and propylene glycol combined with citrate buffer at pH 4.0–5.0; phosphate buffers above pH 6.5 and heat sterilization are avoided because the 6-chloro group and acetoxy esters are susceptible to alkaline hydrolysis and thermal degradation. The bulk solution is prepared in a closed stainless-steel vessel under nitrogen overlay, filtered through a 0.45 µm clarifying filter followed by a 0.22 µm sterilizing-grade polyethersulfone membrane. Filter compatibility is tested with a minimum filtration flux of 20 L/m²·min and differential pressure not exceeding 1.5 bar. Terminal sterilization by autoclaving at 121°C for 15 min is not recommended without supporting degradation data because ester hydrolysis in aqueous media above 60°C is significant; therefore aseptic filtration followed by filling in an ISO 14644-1 Grade A environment is the default route. The solution is filled into Type I borosilicate glass vials with elastomeric closures under nitrogen headspace. Quality release includes bacterial endotoxins ≤ 0.25 EU/mL per USP <85>, particulate matter per USP <787> (≤ 6000 particles/container ≥ 10 µm and ≤ 600 particles/container ≥ 25 µm for large-volume parenterals; small-volume limits per USP <788>), and visual inspection per USP <790>. The terminal dosage form is a sterile filtered injectable solution supplied in Type I glass vials; administration route and dilution are defined by the clinical label, not by this processing route. For this specific molecule, published compatibility data with rubber closures and plastic tubing is limited; therefore an extractables and leachables study under ICH Q3D and USP <1663>/<1664> is recommended before registration.

Freeze-dried drug product is prepared when the ester-labile molecule is insufficiently stable in an aqueous solution to support shelf life. A bulk solution containing the API and 4.0–5.0% w/v mannitol as a crystallizing bulking agent is formulated in water-for-injection with 0.5–1.0% w/v polyethylene glycol 400 as a co-solvent. Thermal characterization by differential scanning calorimetry identifies the critical formulation temperature; the shelf temperature is set below the collapse temperature during primary drying. The solution is filtered through a 0.22 µm membrane, filled into Type I glass vials with a target fill volume of 2.0–10.0 mL, and partially stoppered. Lyophilization begins with freezing at -45°C for 4 h, followed by primary drying at -20°C shelf temperature and 80–120 mTorr chamber pressure for 24–36 h, and secondary drying at 25°C for 6–8 h at 50 mTorr. Residual moisture by USP <921> Karl Fischer is controlled to ≤ 1.0% w/w. The vials are stoppered under vacuum and sealed with aluminum flip-off caps; container closure integrity is verified by vacuum decay per USP <1207>. Reconstitution with sterile water for injection at 20–25°C yields a clear to slightly hazy solution in less than 3 min without visible particles. The terminal product is a sterile lyophilized powder for injection intended for immediate reconstitution and administration; no terminal heat sterilization is applied. Because the 6-chloro substituent may hydrolyze in reconstituted solution, the in-use stability period is established by HPLC assay and related substance testing at 0, 2, 4, and 8 h after reconstitution.